[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-pulmonary-embolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-pulmonary-embolism":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,41,68,97,126,162,190,211,231,256,281,303],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100579097","a-real-world-study-of-ekosonic-endovascular-system-in-chinese-populations-with-acute-pulmonary-embolism-100579097",false,"NCT06819865","A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism","EkoSonic Endovascular System in China RWS(ANTEATER)","ANTEATER","Inclusion Criteria:\n\n1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \\\u003C 14 days).\n2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image\n3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.\n\nExclusion Criteria:\n\n1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \\\u003C 14 days).\n2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image\n3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","6 Months","OBSERVATIONAL","This study to collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.",[26],"Acute Pulmonary Embolism",[28],"PE","NOT_YET_RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":21},"2026-05-30",{"date":37,"type":21},"2028-07-30",{"name":39,"class":40},"Boston Scientific Corporation","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100636528","clinical-scores-biomarkers-and-ct-findings-in-acute-pulmonary-embolism-100636528","NCT07566858","Clinical Scores, Biomarkers, and CT Findings in Acute Pulmonary Embolism","Comparing Clinical Scores, Biomarkers, and CT Findings in Patients With Acute Pulmonary Embolism Across Different Hospital Departments","PEST","Inclusion Criteria:\n\n* • Adults aged ≥ 18 years\n\n  * Confirmed acute pulmonary embolism by CTPA\n\nExclusion Criteria:\n\n* • Chronic pulmonary embolism\n\n  * Non-diagnostic CTPA\n  * Refusal to participate\n  * Severe renal impairment precluding contrast-enhanced CT\n  * Known hypersensitivity to contrast media",{"count":50,"type":21},50,"This study aims to compare clinical scoring systems, laboratory biomarkers, and computed tomography (CT) findings in patients diagnosed with acute pulmonary embolism in different hospital departments.\n\nThe study will include patients diagnosed with acute pulmonary embolism at Sohag University Hospital. Clinical data, laboratory results, and imaging findings will be collected and analyzed to evaluate their diagnostic and prognostic value.\n\nThe goal of this research is to identify the most reliable and practical tools for early diagnosis and risk stratification of acute pulmonary embolism, which may help improve patient management and outcomes.\n\nThis is an observational study and does not involve any intervention or change in standard patient care.",[26],[26,54,55,56,57],"Pulmonary Embolism","CT Pulmonary Angiography","Clinical Scores","D-dimer","2026-04-27",{"date":60,"type":33},"2026-05-05",{"date":62,"type":21},"2026-05-01",{"date":64,"type":21},"2027-07-01",{"name":66,"class":67},"Sohag University","OTHER",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100324438","registry-of-patients-prescribed-anticoagulation-100324438","NCT03504007","Registry of Patients Prescribed Anticoagulation","Standardized, Guidelines Directed But Patients Oriented Clinical Practice Prospectively Registered","STAGPOR","Inclusion Criteria:\n\n• VTE seen at Thrombophilia Clinic and treatment with anti-coagulant is started within 14 days of VTE diagnosis date.\n\nExclusion Criteria:\n\n* Patients already on anticoagulation for other reasons or enrolled into anticoagulation clinical trials.",{"count":77,"type":21},10000,"The Gonda Vascular Center- Thrombophilia Clinic at Mayo Clinic in Rochester, Minnesota utilizes a standardized, guideline-directed, yet patient-oriented approach for treating patients diagnosed with venous thromboembolism (VTE).This study is the ongoing registry of clinical practice with standardized approach to patient assessment and therapy. As most of registries it does not have any definite number of recruited subjects or the date of study completion but provides anticipated number of recruited subjects and the time of anticipated enrolment which was provided only because of formal requirement related to structure of ClinicalTrials.gov website. This number will be updated and upgraded as we continue this registry.\n\nThe rates of VTE recurrence, major bleeding, clinically relevant non-major bleeding (CRNMB) and survival in patients treated with anticoagulation for acute VTE are assessed during prospective observation. VTE cases include an acute deep vein thrombosis (DVT) of lower or upper extremities, splanchnic veins, gonadal, renal, cerebral veins thrombosis and pulmonary embolism (PE). Therapy includes the whole spectrum of FDA approved anticoagulants such as \"classic\" agents: warfarin and heparinoids and the newer direct oral anticoagulants (DOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban.",[80,26],"Acute Deep Vein Thrombosis",[82,54,83,84,85,86],"Deep Vein Thrombosis","Apixaban","Rivaroxaban","Dabigatran","Edoxaban","RECRUITING","2026-04-22",{"date":58,"type":33},{"date":91,"type":33},"2013-03-01",{"date":93,"type":21},"2033-03",{"name":95,"class":67},"Mayo Clinic",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":96},"100576376","incorporating-healthy-living-strategies-to-aid-in-recovery-after-acute-pulmonary-embolism-100576376","NCT06784492","Incorporating Healthy Living Strategies to Aid in Recovery After Acute Pulmonary Embolism","Recovery After Acute Pulmonary Embolism","ERASE-PE","Inclusion Criteria:\n\n1. English speaking (\\>18 years old). Daily messages will be sent in English.\n2. Acute PE with at least one of the following:\n\n   1. any right ventricular enlargement or dysfunction on echocardiogram;\n   2. CT Angiogram reporting any right ventricular enlargement; or\n   3. elevated cardiac biomarker (NT-pro BNP or troponin above baseline). Criteria for enrollment will be included on source document.\n3. Rate controlled atrial arrythmias (resting heart rate \\\u003C110 beats\u002Fm) are eligible for enrollment. This includes atrial fibrillations. This is standard of care management for atrial fibrillation.\n4. Subjects do need to take prescribed anticoagulation.\n\nExclusion Criteria:\n\n1. Pregnancy.\n2. Cardiac Effort \\>3.5 beats\u002Fm during 6MWT.\n3. Resting tachycardia \\>110 beats\u002Fm at hospital discharge.\n4. Chronic Thromboembolic Pulmonary Hypertension\n5. Systolic blood pressure \\>180 mmHg at hospital discharge.\n6. Inability to walk.\n7. Estimated prognosis \\\u003C12 months at the time of discharge due to underlying co-morbidities (e.g., cancer).\n8. Advanced neurologic disease and would not be able to comply with the messages.\n9. Lack of access to email or text messaging 10. Inability or unwillingness to follow daily instructions.",{"count":106,"type":21},100,"INTERVENTIONAL",[109],"NA","The purpose of the ERAsE-PE study is to determine whether two different healthy living strategies (along with anticoagulation) might aid in recovery after a patient is hospitalized for pulmonary embolism. Specifically, Investigators will compare changes in Cardiac Effort (#heart beats used during the 6-minute walk test\u002Fwalk distance) measured after an 8-week program.",[26],[113,114,115,116],"Recovery acute pulmonary embolism","Six minute walk","Cardiac Effort","actigraphy","2026-04-07",{"date":119,"type":33},"2026-04-08",{"date":121,"type":33},"2025-02-27",{"date":123,"type":21},"2027-12-01",{"name":125,"class":67},"University of Rochester",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":107,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":161},"100631869","home-pe2--home-treatment-versus-hospitalization-in-patients-with-acute-pulmonary-embolism-no-clinical-severity-criteria-and-either-right-ventricular-dysfunction-or-elevated-troponin-a-randomized-controlled-trial-100631869","NCT07506291","HOME-PE2 : Home Treatment Versus Hospitalization in Patients With Acute Pulmonary Embolism, no Clinical Severity Criteria, and Either Right Ventricular Dysfunction or Elevated Troponin: a Randomized Controlled Trial","HOME-PE2","Inclusion Criteria:\n\n* Presentation to the Emergency Department or unscheduled consultation in one of the participating centers\n* Symptomatic PE objectively confirmed according to the European Society of Cardiology criteria 4 (either by i) a high-probability ventilation\u002Fperfusion lung scan, ii) a new contrast filling defect on spiral computed tomography, or iii) a new documentation by ultrasonography of a proximal DVT, i.e., thrombus in the popliteal vein or above, along with clinical signs of PE. All radiological tests used to diagnose PE will be interpreted by on-site radiologists or angiologists)\n* No clinical criteria mandating hospitalization according to the Hestia rule, i.e., negative Hestia rule\n* Right ventricular dysfunction - defined as a right ventricular (RV) to left ventricular (LV) diameter ratio \\> 1.0 on echocardiography (apical four-chamber or subcostal four-chamber view) or on CTPA (transverse plane) OR High-sensibility cardiac troponin I or T concentration above the upper limit of local normal value\n* Insurance cover according to local legislation\n* Age ≥18 years\n* Signed free informed consent (or oral consent if possible according to local regulation).\n\nExclusion Criteria:\n\n* Shock or hypotension (defined as systolic blood pressure \\\u003C90 mmHg or a systolic pressure drop by ≥40 mmHg, for \\>15 minutes, if not caused by new-onset arrhythmia, hypovolemia, or sepsis)\n* Combined right ventricular dysfunction (RV\u002FLV \\> 1.0 on imaging) AND troponin concentration above the upper limit of local normal value\n* Free floating thrombi in the right atrium or ventricle, if identified by routine echocardiography or CTPA\n* Active cancer other than basal or squamous-cell skin cancer defined at least with one of the following: i) cancer diagnosed within the last 6 months, ii) current anti-cancer treatment or during the 6 months before enrollment, iii) locally advanced or metastatic cancer\n* PE diagnosis established since more than 24 hours\n* 48 hours or more elapsed between ED presentation and potential inclusion or other reason making home discharge impossible within the 48 hours since ED presentation\n* Limited life expectancy or any other reason making 3-month follow-up impossible\n* Pregnant or parturient patient\n* Patient in detention by judicial or administrative decision, under a legal protection measure or undergoing compulsory psychiatric treatment",{"count":134,"type":21},568,[109],"This study (HOME-PE2) is a multicenter, randomized controlled trial comparing home treatment versus hospitalization in patients with acute pulmonary embolism (PE) who have no clinical severity criteria according to the Hestia rule but present either right ventricular dysfunction or elevated cardiac troponin levels.\n\nWhile outpatient management is considered safe for low-risk PE patients, the optimal management of patients without clinical severity but with signs of right ventricular strain or myocardial injury remains uncertain, and current guidelines are inconsistent. As a result, most of these patients are still hospitalized despite limited evidence supporting this approach.\n\nThe primary objective is to assess whether home treatment is non-inferior to hospitalization in terms of safety, defined by the 7-day rate of adverse events according to the EARTH consensus. Secondary objectives include evaluation of net clinical benefit, quality of life, functional status, and healthcare resource utilization, as well as exploration of sex-related differences and cost-effectiveness.\n\nA total of 568 adult patients with confirmed PE will be randomized (1:1) to either home treatment with early discharge or standard hospitalization. Patients will be followed for 90 days.",[26],[139,140,141,142,143,144,145,146,147,148,149,150],"pulmonary embolism","Outpatient treatment","Home treatment","Hospitalization","Hestia rule","Right ventricular dysfunction","Troponin","Risk stratification","Randomized controlled trial","Quality of life","Functional status","Health economics","2026-03-26",{"date":153,"type":33},"2026-04-01",{"date":155,"type":21},"2026-06",{"date":157,"type":21},"2029-09",{"name":159,"class":160},"University Hospital, Angers","OTHER_GOV",18,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":107,"phases":172,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":96},"100519060","phase-2-129xe-mri-cardiopulmonary-100519060","NCT06038630","129Xe MRI Cardiopulmonary","129Xe Gas Exchange MRI to Visualize Cardiopulmonary Function","Inclusion Criteria for Healthy Volunteers:\n\n(Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial)\n\n1. Outpatients of either gender, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol (Consent must be given before any study procedures are performed.)\n3. Subject has no diagnosed pulmonary conditions\n4. Subject has not smoked in the previous 5 years\n5. Smoking history, if any, is less than or equal to 5 pack-years\n6. No history of using other inhaled products more than 1\u002Fweek for \\> 1 year\n\nInclusion Criteria for Transfusion and Phlebotomy Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following:\n\n1. Patients who are scheduled to receive a red cell transfusion for anemia.\n2. Patients who are scheduled to undergo therapeutic phlebotomy to treat erythrocytosis or polycythemia\n3. Healthy volunteers undergoing voluntary whole blood donation (healthy volunteer inclusion criteria noted above)\n\nInclusion Criteria for Oxygen Administration Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (ILD, Dyspnea, CTEPH, or Healthy):\n\n1. Interstitial Lung Disease or Dyspnea\n\n   * Physician diagnosis of Interstitial Lung Disease by a pulmonologist using established criteria or physician referral of patient with dyspnea\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\n   OR\n3. Healthy Volunteer (criteria noted above)\n\nInclusion Criteria for Acute or Chronic Pulmonary Embolism Patients:\n\n1. In-patient or outpatients of either sex, age \\> 18\n2. Willing and able to give informed consent and adhere to visit\u002Fprotocol\n\nAnd one of the following categories (Acute or Chronic)\n\n1. Acute Pulmonary Embolism\n\n   * Patients presenting with acute PE 24-48hrs post-admission\n   * Willing to return after 3-6 months of anti-coagulation therapy\n\n   OR\n2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH)\n\n   * Patients with a diagnosis of CTEPH, defined as mean PA pressure \\>20 mmHg with a pulmonary vascular resistance \\>2 WU and pulmonary capillary wedge pressure ≤15 mmHg at right heart catheterization with evidence of chronic thromboembolic disease on clinical imaging after 3 months of anticoagulation\n   * Scheduled for pulmonary thromboendoarterectomy (PTE) surgery and willing to re-turn 3-6 months after for optional follow-up scans\n\nExclusion Criteria for All subjects:\n\nSubjects presenting with any of the following will not be included in the trial:\n\n1. MRI is contraindicated based on responses to MRI screening questionnaire\n2. Subject is pregnant or lactating\n3. Resting O2 saturation \\\u003C90% with maximum supplemental O2 delivered by nasal canula\n4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI\n5. Subject has history of any known ventricular cardiac arrhythmia\n6. Subject has history of cardiac arrest within the last year\n7. Subject does not fit into 129Xe vest coil used for MRI\n8. Subject cannot hold his\u002Fher breath for 10 seconds\n9. Subject deemed unlikely to be able to comply with instructions during imaging\n10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements",true,{"count":171,"type":21},125,[173],"PHASE2","The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.",[176,177,26,178,179,180],"Interstitial Lung Disease","Chronic Thromboembolic Pulmonary Hypertension","Anemia","Polycythemia","Dyspnea","2026-02-02",{"date":183,"type":33},"2026-02-04",{"date":185,"type":33},"2024-01-12",{"date":187,"type":21},"2028-06-30",{"name":189,"class":67},"Bastiaan Driehuys",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":96},"100607555","saline-contrast-electrical-impedance-tomography-method-for-diagnosis-of-acute-pulmonary-embolism-100607555","NCT07190079","Saline Contrast Electrical Impedance Tomography Method for Diagnosis of Acute Pulmonary Embolism","A Multicenter Comparative Study of Saline Contrast Electrical Impedance Tomography Method Versus CTPA in the Diagnosis of Acute Pulmonary Embolism","ECTPED","Inclusion Criteria:\n\n1. Patients with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure;\n2. Availability of CTPA results within 24 hours or scheduled to undergo CTPA within the next 24 hours;\n3. Age \\>18 years; no gender restrictions;\n4. Presence of central venous access (internal jugular or subclavian vein) or peripheral forearm venous access;\n5. Willingness to participate with signed informed consent from either the patient or legal guardian.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation;\n2. Relative contraindications to EIT examination (e.g., chest wall wounds at electrode belt placement site, presence of pacemakers);\n3. Severe hypernatremia (serum sodium \\>155 mmol\u002FL);\n4. Inability to maintain expiratory breath-hold for ≥8 seconds;\n5. BMI \\>50 or severe thoracic deformities;\n6. Current extracorporeal membrane oxygenation (ECMO) therapy.",{"count":199,"type":21},343,"The goal of this observational study is to compare the consistency of saline contrast Electrical Impedance Tomography(EIT) method and Computed Tomography Pulmonary Angiography (CTPA) in diagnosing acute pulmonary embolism. The main question it aims to answer is:\n\nCan bedside saline contrast EIT method be used for the diagnosis of acute pulmonary embolism? The participants will undergo saline contrast EIT and CTPA examinations successively within 24 hours.",[26],"2025-09-28",{"date":204,"type":33},"2025-10-02",{"date":206,"type":33},"2025-09-24",{"date":208,"type":21},"2027-09-15",{"name":210,"class":67},"Peking Union Medical College Hospital",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100585812","the-value-of-novel-thrombus-markers-in-the-diagnosis-and-treatment-of-acute-pulmonary-embolism-100585812","NCT06907238","The Value of Novel Thrombus Markers in the Diagnosis and Treatment of Acute Pulmonary Embolism","Inclusion Criteria:\n\n* 1.Patients diagnosed with APE for the first time through CTPA in clinical practice and who have not received anticoagulant therapy in the past month; 2.Age ≥ 18 years old.\n\nExclusion Criteria:\n\n* 1\\. Complicated with other thrombotic diseases, complicated with important organ damage such as heart, liver, kidney, and previous history of pulmonary embolism; 2. Malignant tumors; 3. Renal dialysis patients; 4. Antiphospholipid syndrome; 5. Immune system diseases; 6. Hematological diseases; 7. DIC caused by severe infection; 8. Patients judged by clinicians to be unfit for clinical practice.","120 Years",{"count":219,"type":21},400,"In response to the high mortality rate of patients with acute pulmonary embolism (APE) and the fact that only a small proportion of deceased patients can receive correct diagnosis, this study will use a sensitive, non-invasive, and feasible new thrombus molecular marker (TAT\u002FPIC\u002FTM\u002Ft-PAIC) to detect and evaluate the activation of the coagulation and fibrinolysis systems and endothelial system damage in patients, in order to monitor the early diagnosis and treatment of APE, reduce mortality, and improve patient quality of life. Therefore, this study intends to include 200 newly diagnosed APE patients to evaluate the sensitivity and specificity of the single and combined application of novel thrombus molecular markers for APE diagnosis; Detect the biomarker results of patients at different time points before and after treatment, and evaluate their value in APE treatment monitoring; Track and follow up on patients after discharge to explore the prognostic value of biomarkers for APE.",[26],"2025-09-16",{"date":224,"type":33},"2025-09-18",{"date":226,"type":21},"2025-10-14",{"date":228,"type":21},"2027-12-31",{"name":230,"class":67},"Beijing Anzhen Hospital",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":107,"phases":241,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":4},"100595405","early-phase-1-mechanical-thrombectomy-for-acute-pulmonary-embolism-100595405","NCT07032025","Mechanical Thrombectomy for Acute Pulmonary Embolism","A Prospective, Multicenter, Randomized Controlled Trial of the Catheter-directed Mechanical Thrombectomy Compared to Standard Anticoagulation for Use in the Treatment of Acute Intermediate-risk Pulmonary Embolism.","Inclusion Criteria:\n\n* Aged 18-75 years (male or female)\n* Clinically diagnosed with acute PE\n* Right ventricular\u002Fleft ventricular diameter ratio (RV\u002FLV) ≥0.9 on computed tomographic pulmonary angiography (CTPA)\n* Provision of voluntary written informed consent.\n\nExclusion Criteria:\n\n* Target vessel diameter \\\u003C6 mm\n* Calcification, plaque, or stenosis in target lesion\n* Sustained systolic blood pressure \\\u003C90 mmHg for \\>15 minutes or requiring vasopressors to maintain SBP ≥90 mmHg\n* Peak pulmonary artery pressure \\>70 mmHg\n* Hematocrit \\\u003C28%\n* History of chronic pulmonary hypertension\n* Pre-existing left bundle branch block\n* Chronic left heart failure with left ventricular ejection fraction (LVEF) ≤30%\n* Renal dysfunction (serum creatinine \\>1.8 mg\u002FdL or \\>159 μmol\u002FL)\n* Known coagulopathy or bleeding diathesis:\n\nPlatelet count \\\u003C50×10⁹\u002FL, or International Normalized Ratio (INR) \\>3\n\n* Contraindications to antiplatelet\u002Fanticoagulant therapy\n* Cardiothoracic or pulmonary surgery within 7 days prior\n* Intracardiac thrombus\n* Patients on extracorporeal membrane oxygenation (ECMO)\n* Known hypersensitivity to iodinated contrast media\n* Significant comorbidities complicating treatment\u002Fevaluation:\n\nActive malignancy Acute infectious disease\u002Fsepsis Systemic conditions precluding procedure tolerance Life expectancy \\\u003C1 year\n\n* Pregnant or lactating women\n* Concurrent participation in other drug\u002Fdevice trials\n* Other investigator-determined unsuitability","75 Years",{"count":240,"type":21},200,[242],"EARLY_PHASE1","Research Objective:\n\nTo prospectively compare the efficacy and safety of a pre-collaboratively developed ultra-thin PTFE minimally invasive thrombectomy system versus standard pharmacological therapy in patients with acute pulmonary embolism (PE), both administered on top of standard care.\n\nResearch Content:\n\nPatients meeting all the following criteria will be enrolled:\n\nAged 18-75 years (male or female)\n\nClinically diagnosed with acute PE\n\nRight ventricular\u002Fleft ventricular diameter ratio (RV\u002FLV) ≥0.9 on computed tomographic pulmonary angiography (CTPA)\n\nProvision of voluntary written informed consent.\n\nStudy Design:\n\nAfter confirming eligibility, subjects will be randomized at a 1:1 ratio into two groups:\n\nInnovative Device Group: Minimally invasive thrombectomy\n\nStandard Pharmacological Therapy Group: Pharmacological thrombolysis + anticoagulation\n\nStudy Endpoints:\n\nPrimary Efficacy Endpoint:\n\nReduction in RV\u002FLV ratio (measured by CTPA) from baseline to 48 hours post-treatment.\n\nPrimary Safety Endpoint:\n\nIncidence of Major Adverse Events (MAEs) from baseline to 48 hours post-treatment, defined as:\n\nProcedure-related death\n\nMajor bleeding (per VARC-2 criteria: life-threatening, disabling, or major bleeding)\n\nTreatment-related clinical deterioration, including:\n\nUnplanned mechanical ventilation\n\nArterial hypotension (systolic blood pressure \\\u003C90 mmHg for \\>1 hour or requiring vasopressors) or shock\n\nCardiopulmonary resuscitation\n\nSustained deterioration in oxygenation\n\nEmergency surgical embolectomy.\n\nKey Terminology Notes:\n\nRV\u002FLV: Right Ventricular\u002FLeft Ventricular diameter ratio (standard medical abbreviation retained).\n\nVARC-2: Valve Academic Research Consortium-2 (internationally recognized bleeding criteria).\n\nPTFE: Polytetrafluoroethylene (material name preserved).\n\nMAE: Major Adverse Events (acronym defined at first use).\n\nClinical deterioration: Explicitly specified with objective clinical indicators.\n\nThis translation maintains scientific precision while adhering to international clinical trial reporting standards (ICH-GCP). The structure aligns with typical English-language study protocols for clarity and reproducibility.",[26],[246,54,247],"Prospective Studies","Thrombectomy","2025-06-13",{"date":250,"type":33},"2025-06-22",{"date":252,"type":21},"2025-07-01",{"date":64,"type":21},{"name":255,"class":67},"RenJi Hospital",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":264,"studyType":23,"phases":4,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":96},"100558034","systemic-thrombolysis-versus-catheter-directed-management-for-acute-intermediate-high-pulmonary-embolism-100558034","NCT06545864","Systemic Thrombolysis Versus Catheter Directed Management for Acute Intermediate-high Pulmonary Embolism","In Hospital Clinical Outcomes and Short Term Follow up of Systemic Thrombolysis Versus Catheter Directed Management for the Treatment of Acute Intermediate-high Pulmonary Embolism","Inclusion Criteria:\n\nPatients diagnosed with acute intermediate-high pulmonary embolism\n\nExclusion Criteria:\n\n* Patients less than 18 years of age.\n* Low risk, intermediate low risk, acute pulmonary embolism\n* patients with RV masses will be excluded.\n* Patient refusal of treatment strategy.",{"count":50,"type":21},"1 Month","To compare in hospital clinical outcomes and one month follow up of systemic thrombolysis versus catheter directed management for the treatment of acute intermediate- high risk pulmonary embolism (using streptokinase or tissue plasminogen activator (TPA) and catheter-based intervention group using Penumbra System).",[26],[268,269,270,271],"intermediate-high","acute pulmonary embolism","systemic thrombolysis","catheter- directed management","2024-08-07",{"date":274,"type":33},"2024-08-09",{"date":276,"type":21},"2024-10-01",{"date":278,"type":21},"2030-03-01",{"name":280,"class":67},"Assiut University",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":290,"studyType":23,"phases":4,"briefSummary":291,"conditions":292,"keywords":293,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":96},"100356077","pulmonary-embolism-warsaw-registry-100356077","NCT03916302","Pulmonary Embolism WArsaw REgistry","PE-aWARE","Inclusion Criteria:\n\n* objectively confirmed pulmonary embolism\n* Informed consent for the participation in the study, according to the requirements of the ethics committee\n\nExclusion Criteria:\n\n* lack of consent",{"count":289,"type":21},1500,"5 Years","Initiated in January 2008, The PE-aWARE (Pulmonary Embolism WArsaw REgistry) is an on-going single-centre prospective observational study of patients with confirmed acute pulmonary embolism (APE). Extensive data on consecutive patients with pulmonary embolism is collected and stored. The main objective is to collect and provide information on patients' characteristics, management, and outcome with the purpose of decreasing mortality in APE, the occurrence of bleeding, and the frequency of thromboembolic recurrences. Moreover, the PE-aWARE registry serves as a basis for creating predictive scores for clinicians which aid patient management. The study endpoints comprise clinically recognized (and objectively confirmed) recurrences of PE, major and minor bleeding complications classified according to the International Society on Thrombosis and Haemostasis classification, need for cardiopulmonary resuscitation or catecholamines, and death.",[26],[269],"2023-10-26",{"date":296,"type":33},"2023-10-27",{"date":298,"type":33},"2008-01-01",{"date":300,"type":21},"2028-12-31",{"name":302,"class":67},"Medical University of Warsaw",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":96},"100522329","study-of-patients-admitted-to-a-cardiac-intensive-care-unit-with-acute-cardiovascular-disease-100522329","NCT06081205","Study of Patients Admitted to a Cardiac Intensive Care Unit With Acute CardioVascular Disease","A Prospective Observational Study of Patients Admitted to a Cardiac Intensive Care Unit Due to Acute CardioVascular Disease.","Inclusion Criteria:\n\n* All patients admitted to the Cardiac Intensive Care Unit (CICU) through the Emergency Department of the UHI\n* All patients transferred to the CICU from other hospital departments or other regional secondary hospitals\n* Patients with an acute cardiovascular disease that requires treatment in a CICU\n* Patients who are under scientific supervision of the 2nd Department of Cardiology\n* Patients (or their relative\u002Flegal representatives) that have signed the informed consent form\n\nExclusion Criteria: None",{"count":311,"type":21},1000,"This is a registry of the patients that are admitted to CICU and treated by the Scientific Staff of the 2nd Department of Cardiology, due to an acute cardiovascular disease (acute coronary syndrome, acute heart failure, arrhythmia, pulmonary embolism, cardiac tamponade etc) in order to investigate the clinical characteristics of the patients, their outcome, identify the factors that could predict the in-hospital mortality and compare the results with the predicted by established risk scores. Furthermore, the study will investigate the one-year mortality and also the major adverse cardiac events (MACE - acute myocardial infarction, stroke, or cardiovascular death) will be measured.",[314,315,26,316],"Cardiogenic Shock","Acute Decompensated Heart Failure","Acute Myocardial Infarction","2023-10-06",{"date":319,"type":33},"2023-10-13",{"date":321,"type":33},"2023-04-27",{"date":323,"type":21},"2027-04-26",{"name":325,"class":67},"University Hospital, Ioannina"]